Immunohistochemistry (IHC): Increase the Success of Biomarker Integration in Clinical Development

“With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, you can increase the success of biomarker integration in clinical development.”

– Amanda Finan, PhD, Head IHC/Histology R&D and Clinical Validations at Cerba Research

Presence and Capabilities – Running Clinical Trials in Australia Infographic

Lab Support for the Largest Global Phase III NASH Study to Date

10-Day Study Start & Custom Test Kit Build at the Height of a Pandemic

Cerba Research initiated custom kit building & distribution for an infectious disease study, during the COVID-19 pandemic, in 10 days. A typical timeline is 8 weeks.

Phase 3 Clinical Trial on the Efficacy and Safety of a New Therapy For Post-Exposure Prophylaxis Of COVID-19 And Other Viral Respiratory Illnesses

Phase 3 Clinical Trial on the Safety and Efficacy Of Combination Therapies in Patients with Either Extensively Drug-Resistant Tuberculosis (XDR-TB), Pre-XDR-TB Or Treatment Intolerant Or Non- Responsive Multi-Drug Resistant Tuberculosis (MDR-TB)

Phase 3 Clinical Trial on the Efficacy and Safety of a New Therapy in the Treatment of Uncomplicated Influenza

Multiple Myeloma – Efficacy and Safety of 2 Different Combination Therapies

COVID-19 Testing at Cerba Research

Fact Sheet – Oncology Clinical Trials at Cerba Research